亚太药业(002370) - 2024 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2024 was ¥84,902,518, representing a 5.18% increase year-over-year, while year-to-date revenue reached ¥306,835,789, up 1.65% compared to the same period last year[3]. - The net profit attributable to shareholders for Q3 2024 was a loss of ¥8,934,704.33, a 51.72% increase in loss compared to the same period last year, with a year-to-date loss of ¥3,459,530.47, reflecting a significant increase of 374.48%[3]. - Total operating revenue for Q3 2024 reached ¥306,835,789.08, an increase from ¥301,858,122.44 in Q3 2023, reflecting a growth of approximately 1.6%[17]. - Operating profit for Q3 2024 was reported at -¥3,202,585.73, an improvement compared to -¥49,291,975.33 in the same period last year[18]. - Net profit for Q3 2024 was -¥3,459,530.47, compared to a net profit of ¥1,260,384.91 in Q3 2023, indicating a significant decline[18]. - The total comprehensive income attributable to the parent company's shareholders was -2,861,149.28 CNY, down from 1,260,384.91 CNY year-on-year[19]. - The basic and diluted earnings per share for Q3 2024 were both -0.0056 CNY, compared to 0.0023 CNY in the previous year[19]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥35,870,275.86, showing a substantial increase of 244.54% compared to the same period last year[10]. - Cash flow from operating activities generated a net inflow of 35,870,275.86 CNY, a significant improvement from a net outflow of -24,816,449.96 CNY in the same period last year[21]. - Cash inflow from sales of goods and services was 193,325,869.73 CNY, compared to 172,369,477.49 CNY in the previous year[20]. - Total cash outflow from operating activities was 171,108,464.35 CNY, down from 211,912,748.33 CNY year-on-year[21]. - The net cash flow from investing activities was -5,107,308.62 CNY, compared to a positive inflow of 2,876,915.08 CNY in the previous year[22]. - The net cash flow from financing activities was -61,901,761.80 CNY, compared to -16,004,922.79 CNY in the same period last year[22]. - The ending balance of cash and cash equivalents was 689,103,730.30 CNY, down from 704,487,317.43 CNY at the end of the previous year[22]. Assets and Liabilities - Total assets at the end of Q3 2024 were ¥1,358,023,867.27, a decrease of 4.99% from the previous year-end, while equity attributable to shareholders increased by 7.67% to ¥625,426,532.05[4]. - The company's total assets as of Q3 2024 were ¥1,358,023,867.27, down from ¥1,429,373,407.82 in Q3 2023, a decrease of about 5%[16]. - Total liabilities decreased to ¥732,597,335.22 from ¥848,498,998.29, reflecting a decline of approximately 13.6%[16]. - The company's equity attributable to shareholders increased to ¥625,426,532.05 from ¥580,874,409.53, an increase of about 7.6%[16]. Investments and Expenses - Research and development expenses decreased by 35.51% to ¥10,253,111.79 compared to the previous year, indicating a reduction in investment in this area[8]. - The company reported a significant increase in investment income of 665.18%, amounting to ¥15,853,845.06, primarily due to the distribution of remaining assets from a joint venture[8]. - Total operating costs decreased to ¥327,680,456.45 from ¥353,686,573.69, marking a reduction of about 7.4% year-over-year[17]. - Research and development expenses decreased to ¥10,253,111.79 from ¥15,897,936.95, a reduction of approximately 35.5%[18]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 64,255[11]. - The largest shareholder, Ningbo Fubon Holdings, holds 14.30% of shares, totaling 89,420,000 shares[11]. - The top ten shareholders include significant stakes from domestic non-state-owned enterprises[11]. - The report indicates no changes in the participation of major shareholders in margin financing and securities lending activities[12]. Other Notable Events - The company completed the transfer of 100% equity of Shanghai New Summit Biopharmaceutical Co., Ltd. for a nominal price of ¥1, while waiving debts of ¥1,456,800[13]. - The company is currently undergoing a capital reduction process following the equity transfer[13]. - The company received government subsidies amounting to ¥1,413,188.10 during the reporting period, contributing to its financial performance[5]. - The company experienced a 100% reduction in short-term borrowings, totaling ¥0.00, as a result of repaying bank loans[7]. - The company reported a 70.16% decrease in contract liabilities, reflecting a reduction in advance payments received[7]. - The company's cash and cash equivalents as of September 30, 2024, amount to ¥689,103,730.30, a decrease from ¥720,474,524.86 at the beginning of the period[14]. - Accounts receivable increased to ¥80,215,026.89 from ¥79,510,294.14[14]. - The company's prepayments decreased to ¥2,014,727.90 from ¥4,244,178.55[14]. - The company's receivables financing decreased to ¥19,738,669.93 from ¥32,288,532.83[14]. - The company has not undergone an audit for the Q3 2024 report[23].